BioSpace News Archive

ONWARD Medical N.V. (Euronext: ONWD), today announced Grégoire Courtine, Ph.D., Professor of Neuroscience at the Swiss Federal Institute of Technology (EPFL) and co-Director of NeuroRestore, demonstrated the effectiveness of ONWARD’s ARC Therapy to stabilize blood pressure after spinal cord injury during his Presidential Special Lecture at NEUROSCIENCE 2021.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that a new analysis comparing pooled LIVMARLI™ (maralixibat) oral solution clinical trial data with a natural history cohort was presented at the American Association for the Study of Liver Diseases annual congress, The Liver Meeting®.

Dr Cassetta was presented with the award at an Awards Ceremony on the evening of 13 November, at the end of the SITC 36th Annual Meeting November 10-13, in Washington DC.

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors.

Eyenuk, Inc. from the EyeArt prospective, multicenter pivotal clinical trial were published as an original investigation in JAMA Network Open, a peer-reviewed medical journal published by the American Medical Association. The article is titled “ Pivotal Evaluation of

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the third quarter and the nine-month period ended September 30, 2021.

Talis Biomedical Corporation, a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, announced the appointment of Brian Blaser to President, Chief Executive Officer and Director.

Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2021.

Fortress Biotech, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.